2014-03-20 12:48:58 UTC

Multitarget Stool DNA Testing for CRC Screening

March 20, 2014

A study in today's issue of New England Journal of Medicine compares multitarget stool DNA tests with fecal immunochemical tests in persons at average risk for CRC.

Stool DNA testing has evolved into what is now a high-performance and robustly validated approach to the screen-detection of colorectal cancer (CRC) and opens exciting new doors for improved effectiveness. In today's issue of New England Journal of Medicine, experts in the field highlight how multitarget stool DNA tests compare with fecal immunochemical tests (FIT) in persons at average risk for CRC.

They report that, in asymptomatic persons at average risk for CRC, multitarget stool DNA testing detected significantly more cancers than did FIT, but had more false positive results. 

Study author, David A. Ahlquist, MD, gives an inside look into stool DNA testing in the latest issue of AGA Perspectives. Read the article.

More on Colorectal Cancer

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Ready for the “Jimmy Kimmel effect”?

March 21, 2018

AGA leader Dr. Christina Ha performed Jimmy Kimmel’s first colonoscopy. Here’s the clip.